Glaxosmithkline’s Volibris Receives Authorisation From The European Commission For The Treatment Of Functional Class II And III PAH

April 28th, 2008 by samospsipsi

GlaxoSmithKline (GSK) announced that the European Commission has issued marketing authorisation for Volibris® (ambrisentan) for the treatment of Pulmonary Arterial Hypertension (PAH) in patients classified as World Health Organisation (WHO) Functional Class II and III, to improve exercise capacity. [i] Efficacy has been shown in idiopathic PAH (IPAH) and in PAH associated with connective tissue disease.

More: continued here

Share and Enjoy:
  • Digg
  • Sphinn
  • del.icio.us
  • Facebook
  • Mixx
  • Google

This entry was posted on Monday, April 28th, 2008 at 11:04 pm and is filed under hypertension. You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.

Leave a Reply

Archives





Categories

Blogroll

Meta